These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33085755)

  • 1. Doxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong.
    Lee SF; Luque-Fernandez MA; Chen YH; Catalano PJ; Chiang CL; Wan EY; Wong IC; Chen MH; Ng AK
    Blood Adv; 2020 Oct; 4(20):5107-5117. PubMed ID: 33085755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular diseases among diffuse large B-cell lymphoma long-term survivors in Asia: a multistate model study.
    Lee SF; Vellayappan BA; Wong LC; Chiang CL; Chan SK; Wan EY; Wong IC; Lambert PC; Rachet B; Ng AK; Luque-Fernandez MA
    ESMO Open; 2022 Feb; 7(1):100363. PubMed ID: 35026723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incident Cardiovascular Diseases Among Survivors of High-Risk Stage II-III Colorectal Cancer: A Cluster-Wide Cohort Study.
    Lee SF; Yip PL; Vellayappan BA; Chee CE; Wong LC; Wan EY; Chan EW; Lee CF; Lee FA; Luque-Fernandez MA
    J Natl Compr Canc Netw; 2022 Oct; 20(10):1125-1133.e10. PubMed ID: 36240841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma.
    Hershman DL; McBride RB; Eisenberger A; Tsai WY; Grann VR; Jacobson JS
    J Clin Oncol; 2008 Jul; 26(19):3159-65. PubMed ID: 18591554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Assessment of Race as a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B-Cell Lymphoma.
    Toure A; Luan D; Wu Y; Christos PJ; Leonard JP; Martin P
    Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):e57-e64. PubMed ID: 34446381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second primary malignancy in diffuse large B-cell lymphoma patients: A SEER database analysis.
    Jiang S; Zhen H; Jiang H
    Curr Probl Cancer; 2020 Feb; 44(1):100502. PubMed ID: 31537411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
    Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
    Oncologist; 2021 May; 26(5):e817-e826. PubMed ID: 33616256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
    Purdum A; Tieu R; Reddy SR; Broder MS
    Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric stroke among Hong Kong Chinese subjects.
    Chung B; Wong V
    Pediatrics; 2004 Aug; 114(2):e206-12. PubMed ID: 15286258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors.
    Salz T; Zabor EC; de Nully Brown P; Dalton SO; Raghunathan NJ; Matasar MJ; Steingart R; Vickers AJ; Svenssen Munksgaard P; Oeffinger KC; Johansen C
    J Clin Oncol; 2017 Dec; 35(34):3837-3843. PubMed ID: 28922087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
    Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
    Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin and cyclooxygenase-2 inhibitors improve survival in newly diagnosed diffuse large B-cell lymphoma: a large population-based study of 4913 subjects.
    Smyth L; Blunt DN; Gatov E; Nagamuthu C; Croxford R; Mozessohn L; Cheung MC
    Br J Haematol; 2020 Nov; 191(3):396-404. PubMed ID: 32304100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
    Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases.
    Rohlfing S; Aurich M; Schöning T; Ho AD; Witzens-Harig M
    Clin Lymphoma Myeloma Leuk; 2015 Aug; 15(8):458-63. PubMed ID: 25899891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry.
    Oerlemans S; Issa DE; van den Broek EC; Nijziel MR; Coebergh JW; Huijgens PC; Mols F; van de Poll-Franse LV
    Ann Hematol; 2014 Oct; 93(10):1705-15. PubMed ID: 24807105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.